Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Dublin, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/2hqvvj/malignant) has announced the addition of the "Malignant Melanoma Pricing and Reimbursement" report to their offering.
With several new high cost melanoma drugs available, payer decisions on whether patients can access those drugs and under what conditions are becoming more important than ever. This report covers both analysis of past payer decisions and forward looking views based on payer interviews.
Key findings
- Prices of melanoma therapies and oncology drugs on the whole have become subject to closer scrutiny due to their high costs
- US payers have few tools for the utilization management of melanoma medicines due to limited treatment options
- Yervoy, Zelboraf, and Tafinlar fared well in health technology assessments in France and Germany, but have had limited uptake in more cost conservative markets due to their high costs
Key Topics Covered:
1. Executive Summary
2. Market Context
- Market entry of new drugs will dramatically increase the budget impact of melanoma treatments
- Marketed malignant melanoma products in the US, Japan, and five major EU markets
- Pipeline malignant melanoma treatments in late-stage development
- Price assumptions
- Bibliography
3. US
- Pricing
- Reimbursement
- Bibliography
4. Japan
- Successful pricing outcomes hinge on receipt of a pricing premium
- Nivolumab was awarded a 60% innovation margin
- Bibliography
5. Five Major EU Markets
- Pricing
- Reimbursement and health technology assessment
- Bibliography
For more information visit http://www.researchandmarkets.com/research/2hqvvj/malignant
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology
